Setting

Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Region

Published: 29 Dec 2020 | Report Code: 10247816 | Pages: 194

Global pharmaceutical CDMO market will reach $289.2 billion by 2030, growing by 6.9% annually over 2020-2030 driven by increasing demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures. Highlighted with 96 tables and 86 figures, this 194-page report “Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Region” is based on a comprehensive research of the entire global pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Region. Based on Category, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Service Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Pharmaceutical Contract Manufacturing Organization (CMO) • Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing) • Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs) • Secondary Packaging Pharmaceutical Contract Research Organization (CRO) • CRO for Pre-clinical Development • CRO for Phase I Trials • CRO for Phase II Trials • CRO for Phase III Trials • CRO for Phase IV Trials • Laboratory Services • Consulting Services • Data Management Services Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical & Biopharmaceutical Companies • Medical Device Companies • Academic Institutes Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (Saudi Arabia, UAE, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Company Profiles of CMO: Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH 8.3.2 Company Profiles of CRO: Charles River Laboratories CMIC Co. Ltd Covance Inc. Hangzhou Tigermed Consulting Co Ltd ICON Plc IQVIA Holdings Inc. LSK Global Pharma Service Co Ltd Novotech Pty Ltd PAREXEL International Corporation Pharmaceutical Product Development LLC (PPD) PRA Health Sciences Inc. Quanticate Ltd Samsung Bioepis Co. Ltd SGS SA (SGS Life Sciences) Syneos Health Inc. WuXi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	10
1.1 Industry Definition and Research Scope	10
1.1.1 Industry Definition	10
1.1.2 Research Scope	11
1.2 Research Methodology	14
1.2.1 Overview of Market Research Methodology	14
1.2.2 Market Assumption	15
1.2.3 Secondary Data	15
1.2.4 Primary Data	15
1.2.5 Data Filtration and Model Design	17
1.2.6 Market Size/Share Estimation	18
1.2.7 Research Limitations	19
1.3 Executive Summary	20
2 Market Overview and Dynamics	23
2.1 Market Size and Forecast	23
2.1.1 Impact of COVID-19 on World Economy	24
2.1.2 Impact of COVID-19 on the Market	27
2.2 Major Growth Drivers	29
2.3 Market Restraints and Challenges	34
2.4 Emerging Opportunities and Market Trends	37
2.5 Porter’s Fiver Forces Analysis	41
3 Segmentation of Global Market by Category	45
3.1 Market Overview by Category	45
3.2 Pharmaceutical Industry	47
3.3 Biopharmaceutical Industry	48
4 Segmentation of Global Market by Service Type	49
4.1 Market Overview by Service Type	49
4.2 Pharmaceutical Contract Manufacturing Organization (CMO)	51
4.2.1 Active Pharmaceutical Ingredients (API)	52
4.2.2 Finished Dosage Formulations (FDF)	53
4.2.3 Secondary Packaging	55
4.3 Pharmaceutical Contract Research Organization (CRO)	56
4.3.1 CRO for Pre-clinical Development	58
4.3.2 CRO for Phase I Trials	59
4.3.3 CRO for Phase II Trials	60
4.3.4 CRO for Phase III Trials	61
4.3.5 CRO for Phase IV Trials	62
4.3.6 Laboratory Services	63
4.3.7 Consulting Services	64
4.3.8 Data Management Services	65
5 Segmentation of Global Market by Therapeutic Application	66
5.1 Market Overview by Therapeutic Application	66
5.2 Infectious Diseases	68
5.3 Oncology	69
5.4 Metabolic Disorders	70
5.5 Cardiovascular Disorders	71
5.6 Central Nervous System	72
5.7 Pulmonary Disorders	73
5.8 Gastrointestinal Disorders	74
5.9 Other Therapeutic Applications	75
6 Segmentation of Global Market by End User	76
6.1 Market Overview by End User	76
6.2 Pharmaceutical & Biopharmaceutical Companies	78
6.3 Medical Device Companies	79
6.4 Academic Institutes	80
7 Segmentation of Global Market by Region	81
7.1 Geographic Market Overview 2019-2030	81
7.2 North America Market 2019-2030 by Country	85
7.2.1 Overview of North America Market	85
7.2.2 U.S.	89
7.2.3 Canada	93
7.2.4 Mexico	95
7.3 European Market 2019-2030 by Country	97
7.3.1 Overview of European Market	97
7.3.2 Germany	101
7.3.3 UK	103
7.3.4 France	105
7.3.5 Spain	107
7.3.6 Italy	109
7.3.7 Russia	111
7.3.8 Rest of European Market	113
7.4 Asia-Pacific Market 2019-2030 by Country	115
7.4.1 Overview of Asia-Pacific Market	115
7.4.2 Japan	119
7.4.3 China	122
7.4.4 Australia	124
7.4.5 India	126
7.4.6 South Korea	128
7.4.7 Rest of APAC Region	130
7.5 South America Market 2019-2030 by Country	132
7.5.1 Argentina	135
7.5.2 Brazil	137
7.5.3 Chile	139
7.5.4 Rest of South America Market	141
7.6 MEA Market 2019-2030 by Country	142
7.6.1 UAE	145
7.6.2 Saudi Arabia	147
7.6.3 South Africa	149
7.6.4 Other National Markets	151
8 Competitive Landscape	152
8.1 Overview of Key Vendors	152
8.2 New Product Launch, Partnership, Investment, and M&A	156
8.3 Company Profiles	157
8.3.1 Company Profiles of CMO	157
Aenova Group	157
Baxter BioPharma Solutions	159
Boehringer Ingelheim	160
Catalent Inc.	161
Famar S.A.	162
Hospira, Inc.	163
Jubilant Life Sciences Ltd.	164
Lonza Group	165
Patheon Inc.	166
Pfizer CentreSource	167
Recipharm AB	168
Vetter Pharma International GmbH	169
8.3.2 Company Profiles of CRO	171
Charles River Laboratories	171
CMIC Co. Ltd	173
Covance Inc.	174
Hangzhou Tigermed Consulting Co Ltd	175
ICON Plc	176
IQVIA Holdings Inc.	177
LSK Global Pharma Service Co Ltd	178
Novotech Pty Ltd	179
PAREXEL International Corporation	180
Pharmaceutical Product Development LLC (PPD)	181
PRA Health Sciences Inc.	182
Quanticate Ltd	183
Samsung Bioepis Co. Ltd	184
SGS SA (SGS Life Sciences)	185
Syneos Health Inc.	186
WuXi AppTec Inc.	187
9 Investing in Global Market: Risk Assessment and Management	188
9.1 Risk Evaluation of Global Market	188
9.2 Critical Success Factors (CSFs)	191
Related Reports and Products	194
List Of Tables

Table 1.  Snapshot of Global Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030	21
Table 2. Growth Rate of World Real GDP, 2017-2021	25
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn	31
Table 4. Worldwide Total Number of Registered Clinical Trials	33
Table 5.  Main Product Trends and Market Opportunities in Global Pharmaceutical CDMO Market	37
Table 6. Global Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	45
Table 7. Global Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	49
Table 8. Global Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn	51
Table 9. Global Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn	52
Table 10. Global Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn	54
Table 11. Global Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn	57
Table 12. Global Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	66
Table 13. Global Pharmaceutical CDMO Market by End User, 2019-2030, $ bn	76
Table 14. Global Pharmaceutical CDMO Market by Region, 2019-2030, $ bn	82
Table 15.  Leading National Pharmaceutical CDMO Market, 2019 and 2030, $ bn	84
Table 16. North America Pharmaceutical CDMO Market by Country, 2019-2030, $ bn	87
Table 17. U.S. Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	91
Table 18. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	91
Table 19. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	91
Table 20. Canada Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	94
Table 21. Canada Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	94
Table 22. Canada Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	94
Table 23. Mexico Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	96
Table 24. Mexico Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	96
Table 25. Mexico Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	96
Table 26. Europe Pharmaceutical CDMO Market by Country, 2019-2030, $ bn	100
Table 27. Germany Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	102
Table 28. Germany Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	102
Table 29. Germany Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	102
Table 30. UK Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	104
Table 31. UK Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	104
Table 32. UK Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	104
Table 33. France Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	106
Table 34. France Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	106
Table 35. France Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	106
Table 36. Spain Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	108
Table 37. Spain Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	108
Table 38. Spain Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	108
Table 39. Italy Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	110
Table 40. Italy Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	110
Table 41. Italy Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	110
Table 42. Russia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	112
Table 43. Russia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	112
Table 44. Russia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	112
Table 45. Pharmaceutical CDMO Market in Rest of Europe by Country, 2019-2030, $ bn	114
Table 46. APAC Pharmaceutical CDMO Market by Country, 2019-2030, $ bn	117
Table 47. Japan Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	121
Table 48. Japan Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	121
Table 49. Japan Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	121
Table 50. China Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	123
Table 51. China Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	123
Table 52. China Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	123
Table 53. Australia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	125
Table 54. Australia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	125
Table 55. Australia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	125
Table 56. India Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	127
Table 57. India Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	127
Table 58. India Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	127
Table 59. South Korea Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	129
Table 60. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	129
Table 61. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	129
Table 62. Pharmaceutical CDMO Market in Rest of APAC by Country, 2019-2030, $ bn	131
Table 63. South America Pharmaceutical CDMO Market by Country, 2019-2030, $ bn	134
Table 64. Argentina Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	136
Table 65. Argentina Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	136
Table 66. Argentina Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	136
Table 67. Brazil Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	138
Table 68. Brazil Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	138
Table 69. Brazil Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	138
Table 70. Chile Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	140
Table 71. Chile Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	140
Table 72. Chile Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	140
Table 73. MEA Pharmaceutical CDMO Market by Country, 2019-2030, $ bn	144
Table 74. UAE Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	146
Table 75. UAE Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	146
Table 76. UAE Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	146
Table 77. Saudi Arabia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	148
Table 78. Saudi Arabia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	148
Table 79. Saudi Arabia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	148
Table 80. South Africa Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	150
Table 81. South Africa Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	150
Table 82. South Africa Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	150
Table 83. Breakdown of Global CMO Market by Key Vendor, 2019, %	154
Table 84. Breakdown of Global CRO Market by Key Vendor, 2019, %	154
Table 85. Aenova Group: Company Snapshot	157
Table 86. Aenova Group: Business Segmentation	157
Table 87. Aenova Group: Product Portfolio	158
Table 88. Aenova Group: Revenue, 2016-2018, $ bn	158
Table 89. Aenova Group: Recent Developments	158
Table 90. Charles River Laboratories: Company Snapshot	171
Table 91. Charles River Laboratories: Business Segmentation	171
Table 92. Charles River Laboratories: Product Portfolio	172
Table 93. Charles River Laboratories: Revenue, 2016-2018, $ bn	172
Table 94. Charles River Laboratories: Recent Developments	172
Table 95.  Risk Evaluation for Investing in Global Market, 2019-2030	189
Table 96. Critical Success Factors and Key Takeaways	192

List Of Figures

Figure 1. Research Method Flow Chart	14
Figure 2. Breakdown of Primary Research	16
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	18
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	20
Figure 5. Global Pharmaceutical CDMO Market, 2019-2030, $ bn	23
Figure 6. Impact of COVID-19 on Business	27
Figure 7. Primary Drivers and Impact Factors of Global Pharmaceutical CDMO Market	29
Figure 8. Primary Restraints and Impact Factors of Global Pharmaceutical CDMO Market	34
Figure 9. Investment Opportunity Analysis	38
Figure 10. Porter’s Fiver Forces Analysis of Global Pharmaceutical CDMO Market	41
Figure 11. Breakdown of Global Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue	45
Figure 12. Global Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)	46
Figure 13. Global Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn	47
Figure 14. Global Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn	48
Figure 15. Breakdown of Global Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue	49
Figure 16. Global Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%)	50
Figure 17. Global Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn	51
Figure 18. Global Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn	52
Figure 19. Global Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn	53
Figure 20. Global Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn	55
Figure 21. Global Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn	56
Figure 22. Global Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn	58
Figure 23. Global Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn	59
Figure 24. Global Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn	60
Figure 25. Global Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn	61
Figure 26. Global Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn	62
Figure 27. Global Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn	63
Figure 28. Global Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn	64
Figure 29. Global Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn	65
Figure 30. Breakdown of Global Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue	67
Figure 31. Global Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)	67
Figure 32. Global Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn	68
Figure 33. Global Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn	69
Figure 34. Global Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn	70
Figure 35. Global Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn	71
Figure 36. Global Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn	72
Figure 37. Global Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn	73
Figure 38. Global Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn	74
Figure 39. Global Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn	75
Figure 40. Breakdown of Global Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue	76
Figure 41. Global Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%)	77
Figure 42. Global Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn	78
Figure 43. Global Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn	79
Figure 44. Global Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn	80
Figure 45.  Global Market Snapshot by Region	81
Figure 46.  Geographic Spread of Worldwide Pharmaceutical CDMO Market, 2019-2030, % of Sales Revenue	82
Figure 47. Global Addressable Market Cap in 2020-2030 by Region, Value ($ bn) and Share (%)	83
Figure 48.  North American Pharmaceutical CDMO Market, 2019-2030, $ bn	86
Figure 49. Breakdown of North America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue	87
Figure 50. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	88
Figure 51. U.S. Pharmaceutical CDMO Market, 2019-2030, $ bn	90
Figure 52. Canada Pharmaceutical CDMO Market, 2019-2030, $ bn	93
Figure 53.  Pharmaceutical CDMO Market in Mexico, 2015-2030, $ bn	95
Figure 54.  European Pharmaceutical CDMO Market, 2019-2030, $ bn	98
Figure 55. Breakdown of European Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue	99
Figure 56. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	100
Figure 57.  Pharmaceutical CDMO Market in Germany, 2019-2030, $ bn	101
Figure 58.  Pharmaceutical CDMO Market in UK, 2019-2030, $ bn	103
Figure 59.  Pharmaceutical CDMO Market in France, 2019-2030, $ bn	105
Figure 60.  Pharmaceutical CDMO Market in Spain, 2019-2030, $ bn	107
Figure 61.  Pharmaceutical CDMO Market in Italy, 2019-2030, $ bn	109
Figure 62.  Pharmaceutical CDMO Market in Russia, 2019-2030, $ bn	111
Figure 63.  Pharmaceutical CDMO Market in Rest of Europe, 2019-2030, $ bn	113
Figure 64. Asia-Pacific Pharmaceutical CDMO Market, 2019-2030, $ bn	116
Figure 65. Breakdown of APAC Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue	116
Figure 66. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	118
Figure 67.  Pharmaceutical CDMO Market in Japan, 2019-2030, $ bn	120
Figure 68.  Pharmaceutical CDMO Market in China, 2019-2030, $ bn	122
Figure 69.  Pharmaceutical CDMO Market in Australia, 2019-2030, $ bn	124
Figure 70.  Pharmaceutical CDMO Market in India, 2019-2030, $ bn	126
Figure 71.  Pharmaceutical CDMO Market in South Korea, 2019-2030, $ bn	128
Figure 72.  Pharmaceutical CDMO Market in Rest of APAC, 2019-2030, $ bn	130
Figure 73. South America Pharmaceutical CDMO Market, 2019-2030, $ bn	133
Figure 74. Breakdown of South America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue	133
Figure 75. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	134
Figure 76.  Pharmaceutical CDMO Market in Argentina, 2019-2030, $ bn	135
Figure 77.  Pharmaceutical CDMO Market in Brazil, 2019-2030, $ bn	137
Figure 78.  Pharmaceutical CDMO Market in Chile, 2019-2030, $ bn	139
Figure 79.  Pharmaceutical CDMO Market in Rest of South America, 2019-2030, $ bn	141
Figure 80. Pharmaceutical CDMO Market in Middle East and Africa (MEA), 2019-2030, $ bn	143
Figure 81. Breakdown of MEA Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue	143
Figure 82. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	144
Figure 83.  Pharmaceutical CDMO Market in UAE, 2019-2030, $ bn	145
Figure 84.  Pharmaceutical CDMO Market in Saudi Arabia, 2019-2030, $ bn	147
Figure 85.  Pharmaceutical CDMO Market in South Africa, 2019-2030, $ bn	149
Figure 86. Growth Stage of Global Pharmaceutical CDMO Industry over the Forecast Period	152


Key Players (this may not be a complete list and extra companies can be added upon request): 
Company Profiles of CMO:
Aenova Group	
Baxter BioPharma Solutions	
Boehringer Ingelheim	
Catalent Inc.	
Famar S.A.	
Hospira, Inc.
Jubilant Life Sciences Ltd.	
Lonza Group	
Patheon Inc.	
Pfizer CentreSource	
Recipharm AB	
Vetter Pharma International GmbH	
8.3.2 Company Profiles of CRO:
Charles River Laboratories	
CMIC Co. Ltd	
Covance Inc.	
Hangzhou Tigermed Consulting Co Ltd	
ICON Plc	
IQVIA Holdings Inc.	
LSK Global Pharma Service Co Ltd	
Novotech Pty Ltd	
PAREXEL International Corporation	
Pharmaceutical Product Development LLC (PPD)	
PRA Health Sciences Inc.	
Quanticate Ltd	
Samsung Bioepis Co. Ltd	
SGS SA (SGS Life Sciences)	
Syneos Health Inc.	
WuXi AppTec Inc.